

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BEUVINK ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/001849

FILED: 22 FEBRUARY 2005

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: P53 WILD-TYPE AS BIOMARKER FOR THE TREATMENT WITH
MTOR INHIBITORS IN COMBINATION WITH A CYTOTOXIC
AGENT**MS: Amendment**Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/001849, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909
Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Date: August 22, 2006

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

1AP9 Rec'd PCT/PTO 23 AUG 2006

ATTY. DOCKET NO.

33584-US-PCT

APPLICATION NO.

Not Yet Known

APPLICANT

BEUVINK ET AL.

FILING DATE

Herewith

Group

10/590406

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,521,407	2/18/03	Warenius et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	02/066019	8/29/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Huang et al., "Mechanisms of Resistance to Rapamycins", Drug Resistance Updates, Vol. 4, No. 6, pp. 378-391 (2001).
	AS	Hosoi et al., "Rapamycin Causes Poorly Reversible Inhibition of mTOR and Induces P53-Independent Apoptosis in Human Rhabdomyosarcoma Cells", Cancer Research, Vol. 59, No. 4, pp. 886-894 (1999).
	AT	Huang et al., "P53/P21CIP1 Cooperate in Enforcing Rapamycin-Induced G1 Arrest and Determine the Cellular Response to Rapamycin", Cancer Research, Vol. 61, pp. 3373-3381 (2001).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

IAP9 Rec'd PCT/PTO 23 AUG 2006

ATTY. DOCKET NO.

33584-US-PCT

APPLICATION NO.

Not Yet Known

APPLICANT

BEUVINK ET AL.

FILING DATE

Herewith

10/590406

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BA	Hosoi et al., "Studies on the Mechanism of Resistance to Rapamycin in Human Cancer Cells", Molecular Pharmacology, Vol. 54, pp. 815-824 (1998).
	BB	Tian et al., "P21WAF1/CIP1 Antisense Therapy Radiosensitizes Human Colon Cancer by Converting Growth Arrest to Apoptosis", Cancer Research, Vol. 60, No 3, pp. 679-684 (2000).
	BC	
	BD	
	BE	
	BF	
	BG	
	BH	
	BI	
	BJ	
	BK	
	BL	
	BM	
	BN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.